Arcutis Enrolls First Patient in Phase 1b Alopecia Areata Study Evaluating ARQ-255
05 déc. 2022 08h00 HE
|
Arcutis Biotherapeutics, Inc.
ARQ-255 is a topical janus kinase (JAK) inhibitor therapy specifically designed as a potential treatment for alopecia areataProprietary Deep Dermal Drug Delivery (4D) formulation designed to deliver...